Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | lamin | 0.0026 | 1 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0025 | 0.8593 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.8593 | 1 |
Echinococcus multilocularis | musashi | 0.0026 | 1 | 1 |
Trichomonas vaginalis | chaperonin, putative | 0.0024 | 0.7795 | 0.5 |
Echinococcus multilocularis | lamin dm0 | 0.0026 | 1 | 1 |
Schistosoma mansoni | intermediate filament proteins | 0.0026 | 1 | 1 |
Echinococcus granulosus | lamin dm0 | 0.0026 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.8593 | 1 |
Loa Loa (eye worm) | T-complex protein 1 | 0.0024 | 0.7795 | 0.7795 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0026 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0025 | 0.8593 | 1 |
Echinococcus granulosus | intermediate filament protein | 0.0026 | 1 | 1 |
Onchocerca volvulus | 0.0026 | 1 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0025 | 0.8593 | 0.8593 |
Trichomonas vaginalis | chaperonin-60kD, ch60, putative | 0.0024 | 0.7795 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.8593 | 1 |
Schistosoma mansoni | lamin | 0.0026 | 1 | 1 |
Echinococcus granulosus | lamin | 0.0026 | 1 | 1 |
Brugia malayi | T-complex protein 1, beta subunit | 0.0024 | 0.7795 | 0.7795 |
Brugia malayi | T-complex protein 1, beta subunit | 0.0024 | 0.7795 | 0.7795 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.8593 | 0.8593 |
Loa Loa (eye worm) | intermediate filament protein | 0.0026 | 1 | 1 |
Schistosoma mansoni | lamin | 0.0026 | 1 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0025 | 0.8593 | 1 |
Onchocerca volvulus | 0.0026 | 1 | 0.5 | |
Brugia malayi | hypothetical protein | 0.0016 | 0.1458 | 0.1458 |
Giardia lamblia | TCP-1 chaperonin subunit beta | 0.0024 | 0.7795 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0025 | 0.8593 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0026 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.9606 | 0.9606 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.8593 | 1 |
Entamoeba histolytica | T-complex protein 1 beta subunit, putative | 0.0024 | 0.7795 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ratio (binding) | = 4.44 | Selectivity ratio of ID50 in liver and heart | ChEMBL. | 2913295 |
Relative ED50 (functional) | 0 | Potency of the compound for induction of GPDH(mitochondrial cytochrome C3-phosphoglycerate oxidoreductase) was measured 48 hours after single intramuscular injection relative to T3 in liver; F is full agonist, potency not determined | ChEMBL. | 2913295 |
Relative ED50 (functional) | 0 | Potency of the compound for induction of GPDH(mitochondrialcytochrome C 3-phosphoglycerate oxidoreductase) was measured 48 hr after single im injection relative to T3 in heart; LM=low maximal response after 2 daily doses of 50 mg/kg | ChEMBL. | 2913295 |
Relative IC50 (binding) | = 0.96 | Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine | ChEMBL. | 2913295 |
Relative IC50 (binding) | = 3.5 | Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart | ChEMBL. | 2913295 |
Relative ID50 (binding) | = 0.54 | In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration | ChEMBL. | 2913295 |
Relative ID50 (binding) | = 2.4 | In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration | ChEMBL. | 2913295 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.